196 related articles for article (PubMed ID: 20847676)
21. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
22. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.
Petsoglou C; Balaggan KS; Dart JK; Bunce C; Xing W; Ali RR; Tuft SJ
Br J Ophthalmol; 2013 Jan; 97(1):28-32. PubMed ID: 23087419
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
24. Subconjunctival bevacizumab for corneal neovascularization.
Erdurmus M; Totan Y
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
[TBL] [Abstract][Full Text] [Related]
25. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
Jeong JH; Chun YS; Kim ES; Kim JC
Cornea; 2011 Oct; 30(10):1071-7. PubMed ID: 21775887
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
27. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
28. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab for corneal neovascularization.
Jacobs DS; Lim M; Carrasquillo KG; Rosenthal P
Ophthalmology; 2009 Mar; 116(3):592-3; author reply 593-4. PubMed ID: 19264217
[No Abstract] [Full Text] [Related]
30. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
Kim EK; Kong SJ; Chung SK
Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
[TBL] [Abstract][Full Text] [Related]
31. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
32. [Subconjunctival injection of bevacizumab for treatment of corneal neovascularization after perforating keratoplasty].
Maier MM; Erben A; Khoramnia R; Zapp D; Winkler von Mohrenfels C; Lohmann C
Klin Monbl Augenheilkd; 2009 Jul; 226(7):573-5. PubMed ID: 19644805
[No Abstract] [Full Text] [Related]
33. Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children.
Elbaz U; Mireskandari K; Shen C; Ali A
Cornea; 2015 Jul; 34(7):773-7. PubMed ID: 25811720
[TBL] [Abstract][Full Text] [Related]
34. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
35. Subconjunctival bevacizumab for vascularized rejected corneal grafts.
Awadein A
J Cataract Refract Surg; 2007 Nov; 33(11):1991-3. PubMed ID: 17964413
[TBL] [Abstract][Full Text] [Related]
36. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
Ahn YJ; Hwang HB; Chung SK
Korean J Ophthalmol; 2014 Apr; 28(2):177-80. PubMed ID: 24688262
[TBL] [Abstract][Full Text] [Related]
37. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.
Carrasco MA
Cornea; 2008 Jul; 27(6):743-5. PubMed ID: 18580272
[TBL] [Abstract][Full Text] [Related]
38. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome.
Uy HS; Chan PS; Ang RE
Cornea; 2008 Jan; 27(1):70-3. PubMed ID: 18245970
[TBL] [Abstract][Full Text] [Related]
39. Combined scraping, coagulation, and subconjunctival bevacizumab in Descemet stripping automated endothelial keratoplasty for bullous keratopathy.
Chiang CC; Lin JM; Tsai YY
Eur J Ophthalmol; 2013; 23(3):309-15. PubMed ID: 23161181
[TBL] [Abstract][Full Text] [Related]
40. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
